Text or WhatsApp Richard at (808) 600-9260
Lion crestHealthcareInvestmentBanking.com

How Family Offices Invest in Healthcare: Structures, Sectors and 2025 to 2026 Deal Data

Family offices enter healthcare four ways: a direct stake, a co-investment beside a private equity sponsor, a fund commitment or a single-deal SPV. The right route depends on two things, the size of the equity check and whether the office has people who can diligence billing, licensing and payer contracts. Without that staff, start with a specialist fund or a co-invest beside one. With physician family members or an operating partner, direct stakes in practice groups become realistic.

The deal flow favors joining existing platforms. Of 148 PE outpatient deals counted in 2025, 119 were add-ons, per PESP data reported by Becker's ASC Review. Platforms are buying far more often than new ones are forming.

Data as of November 20, 2026. Each table names its dataset and period. Worked examples are hypothetical, state their assumptions beside the result, and every derived figure is our arithmetic.

The Data Behind This Guide and What Each Source Measures

None of the deal datasets below separates family office capital from sponsor capital. Each counts a different population, so do not compare figures across rows.

Source (period covered) Population measured What it leaves out Use for a family office
CMS National Health Expenditure fact sheet (2024 actuals, 2025 to 2034 projections) US health spending by service and payer Deals, prices, margins Size of the revenue pools and who pays
Bain & Company, Global Healthcare PE Report 2026 (2025, actuals through November 30, 2025, annualized) Global healthcare PE deal value by sector and region Add-ons below $250 million in the deal count Where large sponsor capital is going and which co-invest slots sponsors will offer
PESP, Private Equity Healthcare Deals: 2025 in Review, via Becker's ASC Review (calendar 2025) PE healthcare deals by subsector, from PitchBook and LevinPro HC Prices and investor types. PESP calls its count likely an underestimate Which outpatient specialties have active platforms
FOCUS Investment Banking, Healthcare EBITDA Multiples: 2026 Dashboard Strategic vs. sponsor multiple gap in therapeutic and technology-driven sectors Other subsectors Which exit buyer to plan for in those sectors
Aswath Damodaran, NYU Stern, EV/EBITDA by sector (January 2026 data) US public-company multiples Private-company discounts Ceiling reference for private prices
SRS Acquiom, 2026 Deal Terms for M&A Escrows (2025 deals) Escrow size and claim rates, all industries Healthcare-only terms Opening reference for escrow at the LOI
Kaufman Hall, Q3 2026 M&A Quarterly Activity Report (released October 13, 2026) Hospital and health system transactions and operating metrics Purchase prices and outpatient deals Divestitures that real estate and operating teams can pursue

Why Healthcare Holds Family Office Capital: The CMS Spending Base

US health spending grew 7.2% to $5.3 trillion in 2024, 18.0% of GDP, per the CMS National Health Expenditure fact sheet. The two pools most family office deals touch are growing faster than the total.

Spending category (CMS, 2024) Amount Growth vs. 2023
Hospital care $1,634.7B +8.9%
Physician and clinical services $1,109.7B +8.1%
Total US health spending $5.3T +7.2%
Payer (CMS, 2024) Amount Share of total
Private health insurance $1,644.6B 31%
Medicare $1,118.0B 21%
Out of pocket $556.6B 11%

CMS projects physician and clinical services spending to grow 5.5% a year on average from 2025 to 2034, with Medicare growing fastest at 7.7% a year and health spending reaching 20.6% of GDP in 2034. For an investor, the payer split matters as much as the growth rate. A practice whose revenue tracks Medicare depends on federal rate setting, while one weighted to commercial payers depends on contract renewals. Ask for payer mix before anything else. For labor cost diligence, the Bureau of Labor Statistics Health Care and Social Assistance page carries current employment and wage data for the sector.

Where Healthcare Private Equity Went in 2025: Bain's $191B Estimate

Bain's press release says global healthcare PE "set a new record in 2025 with an estimated $191 billion in deal value, surpassing the previous peak of 2021." Bain's method, per its physician group report: "2025E represents actual data through November 30, 2025, annualized for the rest of the year." Eleven months are actual deals, and December is projected from that pace.

Bain segment (2025 estimate) Deal value Change vs. 2024 Bain's note
Biopharma $80B Up from $55B Has "accounted for about 30% of overall deal volume and at least 22% of deal value each year since 2020"
Provider and related services $62B +57%
of which: healthcare IT $32B Doubled Bain: "Healthcare IT deal value within the provider segment"
Medtech $33B Nearly doubled "Volume increased nearly 20% to an estimated 88 deals"

Healthcare IT sits inside the $62B provider figure, so it is not added on top. The three top-level segments total $175B by our arithmetic. The press release does not break out the remaining $16B of the $191B.

Region (Bain, 2025 estimates) What Bain reports
North America More than 60% of global provider deal value (physician group report)
Europe On pace to double to an estimated $59B. Biopharma made up the region's top five deals, which accounted for 65% of total deal value, about $38B by our arithmetic (65% × $59B) (press release)
Asia-Pacific A record, more than 30% above the 2021 high despite a second-quarter slowdown (press release)

What this means for a family check. Large biopharma, IT and medtech transactions drove the record, and few family offices can lead deals of that size. Bain's deal count leaves out add-ons below $250 million, which are the deals a family office joins most easily as a co-investor. The headline shows where sponsors are, not the full set of deals open to a family check. The family office capital white paper covers how co-investment raises for add-on programs run.

Four Entry Routes: Direct, Co-Invest, Fund or SPV

Company size and staffing decide the route before preference does. A family office with a small investment team cannot run payer, licensing and coding diligence on a large platform, and it cannot write the full equity check. Richard C. Wilson draws that size line in The Single Family Office:

Only the largest family offices can handle $100 million+ co-investments and even $1B+ single family offices tell me that they are not looking to take on deals in that high range, preferring to take controlling stakes in middle market companies or ride along with a minority position in larger companies or projects.
Richard C. Wilson, book "The Single Family Office"

In healthcare the line falls at the equity check and the diligence load. An office with operators can own a middle-market practice group outright. On a larger platform it comes in as a minority co-investor beside a sponsor that supplies the operating team.

Route Control Healthcare expertise needed Fees Liquidity
Direct on the cap table Highest. You set terms and can take a board seat High. You diligence billing, licensing and ownership yourself No management fee or carry. You pay your own legal and diligence costs Low. Exit depends on a sale or later round
Co-invest beside a sponsor Moderate. Sponsor controls, information rights are negotiated Moderate. You underwrite the sponsor and the deal Often reduced or none Low. Follows the sponsor's exit
Fund LP commitment Lowest. The manager picks deals Low to moderate. You underwrite the manager Management fee plus carry Lowest. Locked for the fund term
SPV (single-deal vehicle) Low. The organizer controls Moderate. You rely on the organizer's diligence Organizer fees and carry on top of deal terms Low. Same as the underlying deal

Match the route to the office (our recommendation, based on staffing):

Office profile Starting route
No healthcare staff, limited monthly hours for one company Fund LP with a healthcare specialist, or co-invest with that same manager
Investment staff, no clinical or reimbursement operators Co-invest beside a sponsor with negotiated information rights
Physician family members or a healthcare operating partner Direct minority or control stake in a practice group, or a club deal
Life sciences or medtech background in the family Specialist venture fund, then co-invest in that fund's later rounds (see the venture section)
Real estate team Medical property under an operating platform, or carved-out hospital facilities (see the hospital section)

Worked example 1 (hypothetical): what fees do to the same outcome.

Assumptions: $10M into one deal returning 2.0x gross ($20M), with all cash back at year five. Fees are paid on top of the $10M. Carry is charged on profit after return of all contributions. Fee and carry rates are illustrations, not a survey of market terms.

Route Assumed terms Total contributed Carry (our arithmetic) Net to family office Net multiple on contributions
Co-invest No fee or carry $10.0M $0 $20.0M 2.00x
SPV 1% a year, 10% carry $10.5M $0.95M (10% × $9.5M profit) $19.05M 1.81x
Fund LP 2% a year, 20% carry $11.0M $1.8M (20% × $9M profit) $18.2M 1.65x

Adding an 8% compounding hurdle with full manager catch-up leaves the fund carry at $1.8M here. The LP's preferred return on $11M over five years is about $5.16M, the deal's $9M profit clears it, and the catch-up restores the manager to 20% of total profit. The fund row buys diversification and a diligence team. The co-invest row buys a better net multiple on one deal you underwrote yourself.

What each capital type means for a founder:

Founder question PE sponsor fund Family office direct Family office co-invest beside a sponsor
What sets the exit date? The fund's term and return targets The family's own horizon, with no fund term forcing a sale The sponsor's fund term
Who supplies operating help? Sponsor operating partners The family's own staff, if it has them The sponsor
Where does follow-on capital come from? The fund and its co-investors The family's balance sheet and any club partners The sponsor first, then co-investors pro rata
Who sits on the board? Sponsor Family representative Sponsor, with an observer seat for the family if negotiated

Terms a co-investor should get in writing:

Term The healthcare angle
Quarterly financials with payer mix and provider headcount Revenue moves with payer contracts and providers, not marketing
Consent over new debt and add-on pricing Add-on multiples and leverage set your equity risk
Cap on sponsor fees charged to the company Monitoring and transaction fees come out of your equity
Pre-emptive rights on follow-on equity Roll-ups raise equity repeatedly, and skipped rounds dilute you
Tag-along on any sponsor sale You exit on the sponsor's price and terms
Same security as the sponsor's fund A different class can sit behind the fund in a downside

Without these terms, a co-invest gives you single-deal concentration with no more control than a fund LP. Our reverse due diligence guide covers how to vet co-investors, and our healthcare deal structures guide covers MSO and JV models.

Sizing a Family Office Check: Equity, Not Enterprise Value

A platform's enterprise value is not the size of the check. Debt funds part of the price, the sponsor's fund takes most of the equity, and co-investors split the rest.

Worked example 2 (hypothetical). Assumptions: $120M enterprise value, $60M of debt, $60M of equity. The sponsor's fund puts in $45M and offers $15M to co-investors. The family office takes $5M. Fees and transaction costs are ignored.

Measure Amount Family office share (our arithmetic)
Enterprise value $120M 4.2%
Equity $60M 8.3%
Co-invest allocation $15M 33.3%
Family office check $5M

Debt makes equity swing harder than business value. With debt held flat at $60M, a 10% rise in enterprise value to $132M lifts equity 20% to $72M and the stake to $6.0M. A 10% fall to $108M cuts equity 20% to $48M and the stake to $4.0M. Get the capital structure, the debt terms and your security class from the sponsor before you size the check.

Our sizing rule of thumb: count rollover equity and co-investments at cost against your healthcare allocation until the platform exits. If one position would take more than half of that allocation, it is a concentrated bet. Cut the check, club with other families, or accept that this deal is your healthcare exposure for several years.

Venture and Life Sciences: The Route Sponsor Data Undercounts

Biopharma is the largest segment in Bain's 2025 estimate at $80B, and Bain says it has accounted for about 30% of healthcare PE deal volume each year since 2020 (press release). Most of that capital goes into large buyouts and carve-outs. Early-stage biotech, medtech and healthtech rounds are a different market with different risk, and families with a scientist or physician in the family often enter here first.

Feature Practice or services buyout Venture biotech, medtech or healthtech
What drives value EBITDA, providers, payer contracts Clinical, regulatory and product milestones
Outcome spread Moderate. Cash flow supports value Wide. Many positions return little, a few drive the return
Diligence skill Billing, coding, licensing, payer contracts Science, trial design, reimbursement path, IP
Follow-on need Add-on equity rounds Multiple rounds before revenue
Sensible family entry Co-invest beside a sponsor Specialist venture fund, then fund co-invests

Practical rules for this route:

What Strategic Buyers Pay: FOCUS's 20% to 40% Premium

FOCUS Investment Banking's 2026 dashboard reports that corporate buyers in therapeutic and technology-driven sectors paid multiples 20% to 40% higher than financial sponsors on a like-for-like EBITDA basis. The finding covers those sectors only. It is not a benchmark for physician, dental, home health or behavioral practice sales, where a comparable strategic bid may not exist.

Public company EV/EBITDA by healthcare industry, US, January 2026 (x EBITDA)
Healthcare IT21.27xHealthcare products19.78xTotal market ex-financials16.95xBiotechnology15.78xPharmaceutical15.25xHealthcare support services11.17xHospitals and facilities8.86x

Public company trading multiples. Private practices usually trade below these.

Chart data
Healthcare IT21.27
Healthcare products19.78
Total market ex-financials16.95
Biotechnology15.78
Pharmaceutical15.25
Healthcare support services11.17
Hospitals and facilities8.86

Source: Aswath Damodaran, NYU Stern, EV/EBITDA by industry, January 2026

The chart uses Aswath Damodaran's EV/EBITDA dataset at NYU Stern, January 2026 data. Damodaran publishes this dataset each January, so these are the latest annual figures as of November 2026, about ten months old. Public multiples move with markets during the year. Use them as a ceiling reference, since private practices trade below public peers.

Worked example 3 (hypothetical). This applies the FOCUS range to an invented company for illustration. It does not reproduce FOCUS's deal set. Assumptions: $10M of EBITDA, entry at a 10.0x sponsor price funded with $50M of debt and $50M of equity, EBITDA and debt flat to exit. Figures are gross, before interest, fees and costs, and are not an IRR.

Exit buyer Multiple Enterprise value Equity value after $50M debt Gross equity multiple on $50M
Financial sponsor 10.0x $100M $50M 1.0x
Strategic at a 20% premium 12.0x $120M $70M 1.4x
Strategic at a 40% premium 14.0x $140M $90M 1.8x

Under these assumptions, buyer type alone moves the equity result from 1.0x to as much as 1.8x. Ask every sponsor which strategics have bought in the subsector and whether they bid on comparable EBITDA.

Run the practice valuation calculator to set value, the deal proceeds calculator to see what reaches equity, and the rollover equity calculator when a physician seller rolls equity. Our healthcare valuation multiples guide covers how private prices relate to public benchmarks.

Escrow and Indemnity: What SRS Acquiom's 2025 Deals Show

The headline price is not the cash at closing. SRS Acquiom's 2026 Deal Terms for M&A Escrows covers 2025 deals across all industries and does not report healthcare separately. Use it as a cross-industry opening reference. Representations and warranties insurance (RWI) makes the largest difference.

Escrow, % of transaction value (SRS Acquiom, 2025 deals, all industries) With RWI: mean With RWI: median Without RWI: mean Without RWI: median
Total escrow 5.1% 2.8% 14.7% 11.1%
General indemnification escrow 2.2% 0.5% 11.3% 10.0%

The same report found indemnification claims, excluding purchase price adjustments, on 28% of deals.

Worked example 4 (hypothetical). Assumptions: a $40M practice sale, escrow sized on the $40M price at the SRS Acquiom all-industry medians.

Scenario Escrow rate Withheld at closing (our arithmetic)
No RWI 11.1% $4.44M
With RWI 2.8% $1.12M
Difference $3.32M less withheld at closing with RWI, before the policy premium

Escrow is cash withheld, not cash lost. How much of it the seller later receives depends on claims made during the survival period and the release terms in the purchase agreement.

Worked example 5 (hypothetical): a physician seller with rollover equity. Assumptions: $2M of EBITDA sold at 8.0x. The physician rolls 20% into platform equity at the entry price. No RWI. Escrow is sized at 11.1% of the full price and withheld entirely from the cash portion. Real documents may size escrow on a different base or split it with the rollover. Taxes, fees and premiums are ignored.

Line Amount (our arithmetic)
Purchase price (8.0 × $2M) $16.0M
Rolled into platform equity (20%) $3.2M
Cash portion $12.8M
Escrow withheld (11.1% × $16.0M) $1.78M
Cash at closing $11.02M
Rollover value if platform equity doubles by exit $6.4M
Rollover value if platform equity falls 20% $2.56M

The rollover carries the platform's debt risk shown in worked example 2. As a buyer or co-investor, a larger escrow protects you against billing and coding problems found after closing. As a seller or holder of rollover equity, it is cash you wait for. Settle RWI, escrow size and survival periods at the LOI. Our LOI red flags checklist lists the terms to fix early.

Outpatient 2025: 148 Counted Deals, 119 Add-Ons, Dermatology and Eye Care on Top

Becker's ASC Review, reporting PESP's 2025 data, says: "There were 148 deals involving outpatient care providers in 2025, including 119 add-on acquisitions." PESP's review draws on PitchBook and LevinPro HC and calls its final count likely an underestimate. Read each count as a floor.

Outpatient measure (PESP, calendar 2025) Deals Share of 148 counted deals (our arithmetic)
Add-on acquisitions 119 80.4%
All other deals (148 minus 119) 29 19.6%
Dermatology 24 16.2%
Eye care 22 14.9%
Oncology 9 6.1%
Most active healthcare subsectors for private equity deals, 2025 (deals)
Health IT151Dental care149Outpatient care148Medtech117Behavioral health56
Chart data
Health IT151
Dental care149
Outpatient care148
Medtech117
Behavioral health56

Source: Private Equity Stakeholder Project, PE healthcare deals 2025 in review

The shares apply to counted deals only. Within them, add-ons outnumbered all other deals about four to one. Bain's physician group report describes the sponsor side: deal volumes have declined from their peak, yet physician groups "remain a major part of many private equity (PE) portfolios."

That pattern favors entering beside an established platform. Take a co-investment slot when the sponsor raises equity for the next add-ons, or hold rollover equity when a physician in the family sells into a platform. An office that builds its own platform from one practice will bid for add-ons against sponsors that already run billing, credentialing and recruiting.

Ask an outpatient platform sponsor:

Question The reason
How many add-ons closed last year, and how many providers left within a year? EBITDA leaves with providers
What multiple did you pay for add-ons, and what do you expect at exit? That gap is the multiple arbitrage you are funding
How much growth came from acquisitions and how much from existing practices? Acquired growth stops when the capital stops
What share of revenue sits in one specialty in one market? Concentrated roll-ups draw antitrust attention and limit exit buyers

Our private equity physician roll-ups guide explains common rollover structures.

For Founders: Raising From a Family Office

A founder pitching a family office is selling to an investment committee of a few people who may not run healthcare deals every week. Make their diligence short.

What to bring Why a family office asks for it
A specific check size against total equity, not enterprise value Families size positions against their healthcare allocation (see worked example 2)
The lead investor and the terms it holds Most families prefer to invest beside a lead on the same security
Payer mix, top five payer contracts and renewal dates Payer concentration is the first healthcare-specific risk they probe
Provider roster with tenure and non-compete status Shows how much EBITDA can walk out the door
Use of proceeds tied to add-ons, sites or hires Families fund plans, not runway
A stated exit path and likely buyer type Sets the horizon against the family's own

If anyone offers to introduce investors for a fee, look up the person and firm on FINRA BrokerCheck before agreeing to anything. It is free and shows registration and disclosure history. Our capital raising guide covers physician investor rounds in detail.

Mapping Family Ownership and Referral Ties Before the LOI

Ownership, referral and review questions can change price, structure or closing timing, and they cost far less to surface before the LOI than after it. A family office can build most of this map itself.

What to map Where to get it How it can change the deal
Every family member, trust and entity that will hold the stake Family office records and the trust officer Sets who appears on the cap table and answers ownership questionnaires
Any family physician who orders from, refers to or practices at the target, its affiliates or its add-on targets The physicians themselves, plus the target's referral reports Can limit board seats, advisory roles or the stake itself
Other healthcare holdings in the same specialty and market Portfolio records, including fund LP positions the manager discloses Adds overlap that buyers and reviewers ask about, and can slow add-ons
How the money is held: taxable account, trust, IRA or retirement plan Custodian and tax adviser Changes after-tax proceeds and which roles the investor can take
Whether the target runs through a management services organization The target's org chart and management agreements Shows what the family owns: the management company, not the practice
Anyone expecting a fee for introducing the deal or the investors The introducer, the sponsor and the company An unplanned fee claim can surface at closing
Expected review steps and their timing The sponsor's deal team Sets a realistic closing date and how long committed cash is tied up

Turning the Ownership Map Into LOI Decisions

A finished map is only useful if each finding leads to a decision before the LOI is signed. Use this table to sort what the map turns up into proceed, restructure or pause.

Map finding Default call before the LOI Practical next step
No family physician has any tie to the target or its add-on targets Proceed Record the answer in writing from each physician and refresh it before each add-on closes
A family physician refers to or practices at the target Restructure before pricing Consider holding the stake through family members or entities with no clinical tie, and decide on board and advisory roles before terms are drafted
The family already holds a position in the same specialty and market Proceed, with a longer timeline Ask the sponsor for its expected review timeline and plan liquidity for the slower end of it
The target operates through a management services organization Reprice on the management agreement Underwrite the management fee, the agreement term and termination rights, since that is the cash flow the family is buying
An introducer expects a fee Pause until settled Get the fee amount, who pays it and the introducer's BrokerCheck record in writing
The stake would sit in an IRA or retirement plan Pause until the custodian confirms Ask the custodian whether it will hold the asset and what roles that allows, and have the tax adviser model proceeds both ways
Review timing is unknown Proceed, with cash held liquid Keep the committed amount in liquid holdings until closing rather than reinvesting it

On the $5M check in worked example 2, a family that pauses on one of these findings before the LOI loses a few weeks. A family that finds the same issue after signing can face a restructured stake, a reset closing date and committed cash sitting idle while it is resolved.

Physician referral ties and practice ownership limits are covered in our healthcare compliance due diligence guide, and premerger and state transaction reviews in our healthcare M&A process guide. For referring physician investors, MSOs, paid introducers and the securities side of a raise, see raising capital from physician investors, management services organizations, choosing a healthcare investment banker and capital raising for healthcare companies, and take the questions those pages raise to your own attorney.

Hospitals in 2026: Kaufman Hall's Q3 Data and the Divestiture Opening

Kaufman Hall's Q3 2026 report, released October 13, 2026, counted 16 hospital and health system transactions in the quarter, matching the same period of 2025. Total transacted revenue reached $8.2 billion, and average seller size approached $586 million. Both measure the annual revenue of the sellers, not purchase price.

Period (Kaufman Hall data, via Becker's Hospital Review) Hospital transactions announced
Q1 2026 22
Q2 2026 18
Q3 2026 16
2026 through Q3 56
Full year 2025 46, the lowest annual count since Kaufman Hall began tracking hospital transactions in 2011

By our arithmetic, the 2026 count through Q3 was already 10 deals above all of 2025.

Large systems are driving activity. Kaufman Hall defines a megamerger as a deal in which the smaller party has more than $1 billion in annual revenue (Becker's). Two were announced in Q3 2026, the third consecutive quarter with megamergers, and Kaufman Hall says 2026 could become a record year for them.

The operating data shows why systems are selling assets:

Hospital metric (Kaufman Hall, year to date as of August 2026) Value
Operating margin, including allocations 2.5%
Hospitals operating at a loss Nearly 43%
Non-labor expense per adjusted discharge vs. 2025 +6%
Supply expense vs. 2025 +5%
Drug expense vs. 2025 +6%

Not-for-profit organizations made up most Q3 acquirers, and divestitures accounted for nearly one-third of announced transactions. The family office opening is in those divestitures, not in mergers. An office with operating partners or a real estate team can pursue carved-out facilities, service lines or property without bidding against not-for-profit systems for whole hospitals. Kaufman Hall does not itemize the divested assets, so each one has to be sourced directly from the selling system.

Divestiture asset Family office fit What to underwrite first
Medical office or outpatient real estate Real estate team Tenant credit, lease term and whether the system stays as tenant
Service line (imaging, lab, ambulatory surgery) Operating partner with that specialty Referral sources after separation and payer contracts that transfer
Whole facility Rarely, without a hospital operator Payer mix and the operating losses the system is shedding

Pre-Investment Checklist for Healthcare Deals

  1. Pick the route from your staffing. Use the route table above before you look at a single deck.
  2. Size against equity, not enterprise value. Get the debt terms and your security class first.
  3. Set escrow and RWI terms at the LOI. The SRS Acquiom 2025 all-industry medians (11.1% total escrow without RWI, 2.8% with it) are the opening reference.
  4. Demand a data room built for this deal. It should include audited financials, payer contracts, licensing records, coding audits and a stated exit path. Without the last three, the documents that show where value can be lost are missing.
  5. Bring your own written questionnaire. Otherwise the pitch deck decides what you examine. Start from our buyer due diligence checklist.
  6. Check the sponsor's own money and the collateral. In practice deals the collateral is often receivables and equipment, and receivables shrink fast once billing or payer problems surface.
  7. Hire a healthcare billing specialist. A generalist checks that the documents agree with each other. A billing specialist checks whether the underlying claims could have been paid.
  8. Finish the ownership and referral map. List every physician owner and family member who refers to the company, and how each investor's money is held.
  9. Visit the site. A clinic visit shows staffing, patient flow and equipment condition that no data room captures.

Questions practice owners and investors ask

How much private equity money went into healthcare in 2025?

Bain & Company's Global Healthcare Private Equity Report 2026 estimates a record $191 billion of global healthcare PE deal value in 2025, above the 2021 peak. Bain built the estimate from actual data through November 30, 2025, annualized for the rest of the year. Biopharma reached an estimated $80 billion, up from $55 billion in 2024. Provider and related services rose 57% to an estimated $62 billion, which includes an estimated $32 billion of healthcare IT. Medtech nearly doubled to an estimated $33 billion. Bain does not separate family office capital from sponsor capital.

Which healthcare sectors draw the most private equity deals?

By Bain's 2025 value estimates, biopharma ($80 billion) leads provider and related services ($62 billion) and medtech ($33 billion). Bain places healthcare IT, an estimated $32 billion, within the provider segment. In outpatient care, Becker's ASC Review reports PESP data showing 148 PE deals in 2025, 119 of them add-ons. Dermatology led with 24, then eye care with 22 and oncology with 9. PESP says its count is likely an underestimate.

Which entry route fits a family office without healthcare staff?

In our view, a fund commitment to a healthcare specialist manager, or a co-investment beside that same manager. Both put billing, licensing and ownership diligence on a team that runs it every week. Direct stakes suit offices with physician family members or a healthcare operating partner. This is a judgment based on deal structure and staffing, not a finding from survey or performance data.

Do strategic buyers pay more than private equity for healthcare companies?

In therapeutic and technology-driven sectors, yes. FOCUS Investment Banking's 2026 dashboard reports that corporate buyers in those sectors paid multiples 20% to 40% higher than financial sponsors on a like-for-like EBITDA basis. FOCUS limits the finding to those sectors, so it is not a benchmark for a typical practice sale. As our arithmetic on a hypothetical company with $10 million of EBITDA and a 10x sponsor bid, a 20% to 40% premium would lift enterprise value from $100 million to between $120 million and $140 million.

How much of a healthcare sale price is held back in escrow?

SRS Acquiom's 2026 Deal Terms for M&A Escrows covers 2025 deals across all industries, not healthcare alone. Total escrow averaged 14.7% of transaction value on deals without representations and warranties insurance (RWI), with a median of 11.1%. On deals with RWI, the average was 5.1% and the median 2.8%. The same report found indemnification claims, excluding purchase price adjustments, on 28% of deals. Escrow is cash withheld at closing. How much the seller later receives depends on claims and the deal's release terms.

Sources